Recently, a meta-analysis investigated the association of treatment with the GLP-1RAs exenatide and liraglutide with bone fractures incidence in T2DM subjects, showing no effects on fracture risk, as compared to placebo or other antidiabetic drugs (glimepiride, sitagliptin, and insulin) [96]. This evidence concerns the gene INS and type 2 diabetes mellitus.